Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’
Publication date: Available online 9 October 2026 Source: ESMO Open Author(s): T. Macarulla, R. Pazo Cid, M.S. Womack, A. Cubillo Gracian, A. Zervoudakis, H. Hatoum, V. Chung, A. Patel, A.S. Paulson, S. Pant, E.M. O’Reilly, R.A. Hubner, E. Van Cutsem, T. Bekaii-Saab, L. Zhang, J. Li, H. Chen, F. Maxwell, Z.A. Wainberg, D. Melisi
Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’. // ESMO Open. – URL: https://www.sciencedirect.com/science/article/pii/S2059702926025354?dgcid=rss_sd_all
Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’. ESMO Open. https://www.sciencedirect.com/science/article/pii/S2059702926025354?dgcid=rss_sd_all
“Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’.” ESMO Open.
@article{article107477,
title = {Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’},
journal = {ESMO Open},
url = {https://www.sciencedirect.com/science/article/pii/S2059702926025354?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment